With the debate swirling around the efficacy and safety of UV-C technology, an individual needs which generation the product is. Infection Control Today® continues its ongoing special reporting on UV-C technology.
Even though the germicidal effects of ultraviolet light were first discovered in 1877, currently in the health care industry, a debate of the efficacy of ultraviolet-C light (UV-C) technology continues. Also, with some investigators publishing studies showing it is safe and others not, the question comes down to which company’s technology works and what does not. Are the studies the companies are using their own, done by an independent research firm, or are the companies using competitors’ data? What generation of UV-C technology are the investigators using?
In the second of 2 segments of this exclusive Infection Control Today® (ICT®) interview with Gunner Lyslo, founder and CEO of Surfacide, continues the discussion on where the industry is going and what questions for health care facilities, schools, businesses, and others should ask when they are looking for UVC technology to keep their employees and visitors safe.
Although, UV-C has been proven to be effectual against SARS-CoV-2, some individuals still are hesitant to consider UV-C technology. Lyslo pushes back and says that second generation technology (like Surfacide) demonstrates that the technology is effective.
“It's an incredibly important technology [and] disinfection modality. And if used in an evidence-based way, with the proper indications for use, it will have a tremendous impact to the benefit of all those end users and all those individuals who are entering those spaces. [This is true] whether it would be a hospital, which hospitals are still first and foremost to [Surfacide], because that's where you're dealing with an immunocompromised patient population, as well as you're dealing with an environmental services team are frontline health care workers who have numerous workplace stresses.”
The first part of the interview with Lyslo is here.
Herpes and Dentistry: A Silent But Serious Concern
February 21st 2025Herpes infections pose significant risks in dentistry. JoAnn Gurenlian, RDH, PhD, presented prevention, treatment, occupational hazards, and a potential breakthrough in gene therapy that could revolutionize herpes management at the Midwinter Meeting.
Chicago Dental Society Honors Drs Joseph Hagenbruch and Mark Lingen for Excellence in Dentistry
February 21st 2025The Chicago Dental Society honored Dr. Joseph Hagenbruch and Dr. Mark Lingen for their leadership, research, and dedication to advancing dentistry and improving oral health care access.
From Sterilization Tech to Infection Control Advocate: Sherrie Busby’s Inspiring Dental Journey
February 20th 2025Sherrie Busby, EDDA, CDSO, CDIPC, shares her journey from dental assisting to infection control advocacy, highlighting her passion for education, her role at Heartland Dental, and her exciting transition to a new chapter.
Innovation and Infection Control: Highlights From W&H at Chicago Dental Midwinter Society Meeting
February 19th 2025Doris Schneider, senior marketing manager for North America for W&H North America, shares insights into the 160th Chicago Dental Society Midwinter Meeting, showcasing the Lexa Mini rapid sterilizer and Sanaa Power handpiece, designed for efficient sterilization and effortless dental procedures.